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INTRODUCTION
Cerebral palsy is themost common neurological disorder in children. Epidemiological
evidence suggests that antenatal origins are a major cause. Currently there is no
antenatal test for cerebral palsy, no proven preventable measures in late pregnancy,
and no known cure. Cerebral palsy affects not only the diagnosed child, but also their
family and the community, requiring considerable social and financial resources to
assist these children in their daily lives.
Cerebral Palsy is a complex, multifactorial disorder, with many different defini-
tions.1 A recent definition of cerebral palsy states that cerebral palsy describes a
group of disorders of the development of movement and posture that are attributed
to non-progressive disturbances that occurred in the developing fetal or infant brain.
The motor disorders of cerebral palsy are often accompanied by disturbances of
sensation, cognition, communication, perception and/or behaviour, and/or by a
seizure disorder.2 Cerebral palsy is characterised by non-progressive, abnormal control
of movement or posture, and is not always diagnosed until months, or even years
after birth.3 Damage to the upper motor neurons of the brain1,4 results in excessive
muscular tonus, spasticity with increased stretch reflexes, and hyperactive tendon
reflexes, all of which are often present in cases of cerebral palsy.1
Despite improvements in obstetric care over the last 50 years, the frequency of
cerebral palsy in most communities has not decreased3,5–9, and may have increased
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slightly as a result of the increased survival rate of infants of very low birthweight.10–12
Caesarean delivery rates have also increased dramatically (up to 6-fold) without any
apparent effect on cerebral palsy rates. Approximately 2 to 2.5 in every 1000 children
born are diagnosedwith cerebral palsy,making it themost common physical disability
in childhood.3,8,9,13 In contrast, there have been substantial decreases in both perinatal
and maternal mortality,3,9 suggesting that poor obstetric care is not a major cause
of cerebral palsy, as had been previously thought.3,6,14–17 Epidemiological studies
indicate that only about 10%of cerebral palsy cases show possible signs of intrapartum
fetal compromise, which may have had recent or longer-standing origins.5,6,18,19 A
recent audit by our group used the 2003 American College of Obstetricians and
Gynecologists/American Academy of Pediatrics criteria to identify acute intrapartum
hypoxia in the maternal and paediatric case notes of 213 cases of cerebral palsy from a
single Australian tertiary care centre born between 1986–2003.20 This audit identified
major antenatal or paediatric cerebral palsy-related pathologies in 98.1% of all these
cases, and that an isolated acute intrapartum hypoxic event was likely in only 2 of 46
neonates born at term and none born preterm.20
There are many risk factors for the occurrence of cerebral palsy, including maternal
and antenatal factors such as prematurity, intrauterine infection, fetal coagulation
disorders, multiple pregnancy, antepartum haemorrhage, breech presentation and
chromosomal or congenital abnormalities.5,6,8,9,14,21–25 This is consistent with other
findings showing that infants with cerebral palsy only occasionally have strong
evidence of primary asphyxia at birth.26 However, the fetus with established brain
dysfunction or susceptibility factors may sometimes experience secondary hypoxia
at birth, ie acute on chronic brain injury. In retrospect no definitive cause can be
identified in more than 75% of cases of cerebral palsy,27 and data indicate that most
children diagnosed with cerebral palsy did not have primary intrapartum asphyxia.
The risk of cerebral palsy is strongly associated with prematurity, occurring 20–30
times more often in infants weighing less than 1500g at birth.28 Very preterm infants
(<32 weeks) represent only 2% of all births but represent 25% of all children with
cerebral palsy.29 Multiple births are also a major risk factor, with twins (especially
monochorionic) at higher risk of developing cerebral palsy than singletons.30 The
risks of having a child with cerebral palsy are 0.2%, 1.3% and 7.6% for singleton,
twin and triplet pregnancies, respectively, and even higher when a co-fetus dies in
utero.30 Nevertheless, at least 50% of all diagnosed cases of cerebral palsy are in term
or near-term infants.31,32
This review describes three new potential antenatal risk factors for cerebral
palsy, namely inherited thrombophilic polymorphisms, cytokine polymorphisms and
exposure to viral infections.
INHERITED THROMBOPHILIAS
The coagulation cascade is the body’s response to a breach in the vascular system,
which is normally balanced by both procoagulation and anticoagulation mechanisms.
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However, there are instances in which this balance is altered, to favour either
procoagulation or anticoagulation. Thrombophilia favours procoagulation and is an in-
herited or acquired condition that predisposes individuals to thromboembolism. Com-
mon inherited thrombophilias include the factor V Leiden (FVL) mutation causing ac-
tivated protein C resistance, the prothrombin gene mutation (PGM), homozygosity or
compound heterozygosity for one or both of the common polymorphisms at positions
677 and 1298 in the gene for 5, 10-methylenetetrahydrofolate reductase (MTHFR) as-
sociated with hyperhomocysteinaemia, and plasminogen activator inhibitor-1 (PAI-1)
genemutation. These inherited thrombophilic conditions predispose to the formation
of thrombosis by impairing the natural coagulation pathway, by promoting excessive
coagulation, by impairing anticoagulation, or by impairing the fibrinolytic pathways.33
Pregnancy results in major haemostatic changes involving decreasing anticoagulation
and increasing coagulation such that with the progression of pregnancy the overall
homeostatic balance of coagulation is altered toward hypercoagulability.34
Endothelial cells play an active role in the coagulation response. When injured,
endothelial cells synthesise and release tissue factor, which initiates coagulation via
the extrinsic pathway of the coagulation cascade. Endotoxin and tumour necrosis
factor (TNF) are among the substrates capable of inducing increased endothelial tissue
factor activity.35,36 TNF is also capable of attenuating the antithrombotic role of
thrombomodulin, by promoting its endocytosis and degradation, and also inhibiting
its transcription. In this way, coagulation is increased, while anticoagulation is
decreased, leading to an overall shift towards a procoagulant state. Given that most
thrombophilias require another risk factor to express the adverse phenotype, the
presence of inflammatory cytokines (perhaps upregulated in response to infection)
in conjunction with an inherited thrombophilia may provoke the development of
thrombosis.
Accumulating epidemiological evidence implicates thrombosis, as well as inflam-
mation, as important factors in the development and causation of cerebral palsy.
One proposed vascular mechanism of cerebral palsy causation is that dislodged
thrombi from the placental circulation may travel to the fetus via the umbilical
vein, ductus venosus, and inferior vena cava, before crossing the patent foramen
ovale to reach the fetal cerebral circulation.37 The potential for widespread damage
from lodgement of the thrombus and blockage of the fetal circulation to the brain
is obvious. Such vascular occlusion could lead to white matter damage such as
periventricular leukomalacia, with subsequent development of cerebral palsy.
The association between the tendency for thrombophilia and cerebral palsy has been
the focus of a number of studies,9,38–41 with FVL shown to be present in 26%of cerebral
palsy cases and only 1.5% of controls in the study by Nelson and colleagues.9 In 1998,
it was proposed that undiagnosed thrombophilias, both inherited and acquired, of the
mother and/or fetus, may be responsible for thrombosis in the maternal and/or fetal
circulation, subsequently resulting in adverse pregnancy outcomes, such as cerebral
palsy.37 There is evidence suggestive of a relationship between cerebral palsy and
placental infarcts, often related to spiral artery thromboses,37,42–44 with one study
identifying thrombi in fetal vessels of the placenta in 11 of 15 infants with cerebral
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Palsy Odds Ratio (95% CI)
MTHFR C677T All Heterozygous Diplegia 1.58 (1.02–2.45)
32–36 Homozygous 2.55 (1.12–5.74)
All types of CP
Heterozygous 1.91 (1.01–3.66)
<32 Homozygous Diplegia 2.76 (1.21–6.12)
MTHFR A1298C 32–36 Heterozygous Diplegia 0.16 (0.02–0.70)




MTHFR + PGM All Homozygous +
heterozygous
Quadriplegia 5.33 (1.06–23.25)
MTHFR = methylenetetrahydrofolate reductase gene, FVL = factor V Leiden, PGM = prothrombin gene
mutation.
palsy.43 However, the literature is by no means conclusive. One study investigating
the link between cerebral palsy and thrombophilia suggested that, in patients with
hemiplegic cerebral palsy, thrombophilia in itself was not an important causative
factor.45 The authors of this study did, however, postulate that the pathogenesis of
cerebral palsy may be related to the interactions between thrombophilias and other
risk factors for cerebral palsy, including maternal and/or neonatal infections46 and
cytokines.47
In both term and near-term infants, major causes of cerebral palsy include intra-
uterine infection and fetal or neonatal stroke.16 A number of studies have investigated
associations between cerebral palsy and the factor V Leiden mutation, with many
cases classified as cerebral palsy caused by fetal or neonatal stroke.9,38,42,48,49 It has
been shown that 40% of cerebral palsy can be clearly identified with vascular factors,
such as infarction and haemorrhage,50 suggesting that thrombophilic polymorphisms,
such as the factor V Leiden mutation, may play important aetiological roles in
cerebral palsy.39
Since then, a large cerebral palsy case-control study has reported that MTHFR
C677T approximately doubles the risk of cerebral palsy in preterm infants, and that
this risk is dependent on the gestational age and cerebral palsy subtype of the infant
(Table 1).41 It appears that these thrombophilia results are only seen in preterm cerebral
palsy infants – no associations were observed between any type of cerebral palsy and
thrombophilia for children born ≥37 weeks gestational age. An additional finding was
the protective effect displayed by the carriage of MTHFR A1298G for diplegic cerebral
palsy (Table 1).41 This is postulated to be the result of homozygosity for MTHFR
A1298G protecting against having the MTHFR C677T polymorphism, probably by
increasing the early embryonic loss rates.51
MTHFR C677T can result in hyperhomocysteinaemia, particularly in conditions of
folate or vitamin B12 deficiency. Hyperhomocysteinaemia may exert thrombophilic
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effects by altering the normal antithrombotic phenotype of the endothelium,
enhancing the activities of factors XII and V, as well as depressing the activation
of protein C, and also by recruiting leukocytes and augmenting leukocyte-
induced endothelial cell activation.52,53 Mild-to-moderate hyperhomocysteinaemia,
with and without the C677T polymorphism, has been linked to arterial disease
and venous thromboembolism.54,55 The thrombophilic tendency associated with
hyperhomocysteinaemia could in itself lead to neonatal stroke, but it appears unlikely
that this mechanism could explain an increased risk of diplegic cerebral palsy in
very preterm infants.56 Preterm birth is a final common pathway of a variety of
pathophysiologic conditions. The association between infection and spontaneous
preterm labour is now well established, and is thought to be responsible for up to
40% of cases, with an especially strong association with very preterm birth.57,58
Recent studies have shown that any inflammatory damage to the vascular lining
could be augmented in a hyperhomocysteinaemic environment by recruiting more
leukocytes and aggravating the leukocyte-induced endothelial damage.55,59,60 The
significant positive association between the polymorphic variant at MTHFR C677
and very preterm infants with cerebral palsy makes an additive adverse interaction
between infection and mild-to-moderate increases in circulating homocysteine an
attractive hypothesis deserving further study.
Homozygous Factor V Leiden was observed to increase the risk for quadriplegia
in very preterm infants, and there was also a 26 fold increased risk of
developing quadriplegia when homozygosity for factor V Leiden was compared
with heterozygosity (Table 1).41 A non-significant trend for heterozygous FVL to be
negatively associated with quadriplegia in very preterm infants was also observed.
Carrying one abnormal FVL allele may protect the vulnerable fetal brain from the
more major degrees of intraventricular haemorrhage by increasing the clotting ability
of the infant, and/or convey some protection in severe infectious processes.61
CYTOKINE POLYMORPHISMS
Cytokines, present in the amniotic fluid, are risk markers of neonatal brain damage
and subsequent long term disability.62 During the course of intrauterine infection,
inflammatory cytokines play a pivotal role in the pathogenesis of brain white matter
damage and the subsequent development of cerebral palsy.47 An association has been
demonstrated between cytokine concentrations from umbilical cord blood and the
development of brain white matter lesions,47 and high expression of TNF alpha (TNF-
) has been demonstrated in neonatal brains with periventricular leukomalacia.63
However, it remains unclear whether the cytokines themselves mediate the damage,
cause the damage, or whether the infection itself is responsible for the damage. A
cytokine hypothesis has been postulated, the so called “Fetal Inflammatory Response
Syndrome” (FIRS), indicating that cytokines act as a final common pathway for
injury to the central nervous system, and that they may be initiated by a number
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Figure 1 Hypothetical schematic diagram illustrating possible causes of cerebral palsy.
of different insults, including infection, hypoxic-ischaemic injury, reperfusion injury,
and toxin-mediated injury.64,65 Finally, the role of proinflammatory cytokines in
preterm birth has been extensively investigated, demonstrating strong associations
between preterm birth and the presence of proinflammatory cytokines.66–71 Preterm
birth is a recognised risk factor for the development of cerebral palsy, suggesting that
the FIRS plays a major pathogenetic role in both preterm birth and cerebral palsy.
Figure 1 is a hypothetical diagram illustrating possible causes of cerebral palsy.
A large number of studies have investigated the association between cytokine
responses to infection and the development of periventricular leukomalacia and/or
cerebral palsy,9,17,47,62,66,67,72–82 as increased levels of cytokines in the amniotic fluid
and fetal circulation appear to increase the risks for both neonatal brain injury and
long-term disability.62 A recent study by Urakubo and colleagues83 demonstrated that
TNF- levels were significantly increased in the placenta when pregnant rats were
injected with lipopolysaccharide (LPS), suggesting that proinflammatory cytokine
levels are increased in the fetal environment in response to maternal infection,
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whichmay significantly impact upon the developing brain. These studies suggest that
cytokines are markers of infection and possible brain damage, and may contribute to
this brain damage via unidentified pathways.
TUMOUR NECROSIS FACTOR-α
Tumour necrosis factor alpha (TNF-) is a 17kDa protein made up of 157 amino
acids. This proinflammatory cytokine is produced in response to infection.84 It
mediates a variety of biologic processes, including growth, development and immune
responses of the brain,85 and is produced by a range of cells, including macrophages,
haematogeneous and neural cells.86 Its main biological function, however, is its
ability to recognise many pathogens and act quickly, promoting a broad range of
immunological and inflammatory responses.84 An excessive cytokine response may
pose more of a risk than the infection. If the production of TNF- is excessive, and is
released systemically in large quantities, fatal complications such as multiple organ
failure may occur.84
TNF- is directly toxic to neurons and may cause white matter damage
associated with periventricular leukomalacia through its cytotoxic effect, damaging
oligodendrocytes.78 TNF- may also disturb developmental transitions from the
oligodendrocyte precursor to the mature oligodendrocyte.87 Cells positive for TNF-
were identified in the whitematter in 9 of 13 periventricular leukomalacia cases when
infant post-mortem tissues were stained with antibodies against TNF-, suggestive of
damage caused by cytokines in the white matter regions of the brain.79 In a separate
study, infants suffering periventricular leukomalacia had increased TNF- and IL-6
in brain tissue, as well as evidence of lymphocytes infiltrating the brain.78 TNF-
also exerts a powerful prothrombotic effect, one of the main mechanisms being the
increased expression of tissue factor.
A study by Yoon et al78 found that the expression of TNF- was more common
with periventricular leukomalacia (88% of cases) than without periventricular
leukomalacia (18% of cases). Concentrations of TNF- in amniotic fluid are
higher in patients with intrauterine infection and subsequent preterm labour.75,80
Proinflammatory cytokines in the brain are higher in infants who died with
periventricular leukomalacia than in infants with no evidence of white matter
damage.47 Higher levels of proinflammatory cytokines were also measured in the
amniotic fluid of preterm infants who later developed cerebral palsy, and in term
infants just days after birth, compared to infants who did not develop cerebral palsy
(both preterm and term).9,88 These studies support a role for an excessive cytokine
fetal inflammatory response leading to periventricular leukomalacia.
About 60% of the variation in TNF- production is genetically determined.89
The TNF-2 polymorphism is located in the promoter region of the gene, and is
a single nucleotide G→A base pair substitution at nucleotide −308 relative to
the transcriptional start site.84 This polymorphism has been associated with high
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Table 2 Significant odds ratios and 95% confidence intervals for TNF-α−308 poly-




(weeks) TNF-α−308 Zygosity Odds Ratio (95% CI)
Hemiplegia <32 Homo- or heterozygous 2.38 (1.02–5.58)
Quadriplegia ≥37 Heterozygous 1.82 (1.04–3.15)
TNF-α = tumour necrosis factor alpha.
levels of TNF-.90–92 In our studies, carriage of the TNF--308 polymorphism was
associated with an increased risk of cerebral palsy, particularly for the development
of quadriplegia in term-born babies (OR 1.82, 95% CI 1.04–3.15) (Table 2).93 These
results suggest that this polymorphism, which has previously been associated with
high circulating TNF- levels, is detrimental to the fetus and can directly or indirectly
cause brain damage. The combination of increased levels of TNF- due to the
polymorphism and the normal physiologic upregulation of TNF- as a result of
infection may contribute to the pathogenesis of white matter damage and subsequent
cerebral palsy.
MANNOSE BINDING LECTIN
Mannose-binding lectin (MBL) is a serum protein involved in the activation of
the complement system of the innate immune system and is involved in the
fetal inflammatory response to injury and infection. The MBL gene has 6 known
polymorphic sites,94 which together result in haplotypes associated with high (HYPA),
intermediate (LYQA, LYPA), low (LXPA) and defective (HYPD, LYQC, LYPB) levels of
circulating MBL.95
The first report of associations between recurrent infections and low levels of MBL
was in 1989.96 Since then, there have been many papers published investigating the
associations between MBL efficiency and increased susceptibility to infection. It is
important to note that 90% of MBL deficient individuals do not acquire repeated
infections, possibly due to the redundancy of the complement system.97 It can be
postulated that the phenotypical manifestation of MBL deficiency is only apparent
when combined with another immunodeficiency, either acquired or genetically
determined. It has been shown that MBL deficient children presenting with recurrent
infection also had concomitant or transient IgG subclass deficiency.98 Because the
MBL pathway plays an important role in eliminating pathogens, especially in neonates
and infants,99 fetuses deficient in MBL may be more susceptible to subclinical
infections and/or inflammatory events in utero.100 Decreased levels of MBL resulting
from polymorphisms in this gene may contribute to the pathogenesis of cerebral palsy
via a decreased response to neurotropic viruses or other infections.
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Table 3 Significant odds ratios and 95% confidence intervals for associations between cerebral
palsy and specified MBL haplotypes. Results are compared against the wild-type HYPA haplotype.104
Viruses investigated included enteroviruses; herpes simplex viruses 1 and 2; Epstein-Barr virus;





(weeks) Odds Ratio (95% CI)
Not considered All Cerebral Palsy LYPA All 1.57 (1.00–2.46)
<37 2.43 (1.41–4.18)
<32 2.54 (1.34–4.76)
Diplegia LYPA 32–36 3.70 (0.80–13.72)
Hemiplegia LYPA <37 2.77 (1.02–7.26)
<32 4.48 (1.55–12.65)






Diplegia LYQA <37 0.31 (0.08–0.91)
Positive viral
exposure
All Cerebral Palsy LYPA <32 3.67 (0.91–12.56)
Hemiplegia LYPA <32 8.25 (1.08–52.76)
Quadriplegia LYQA ≥37 3.56 (1.27–10.30)
HYPD All 5.24 (1.03–21.67)
<32 18.33 (2.06–150.68)
Mutations in the MBL gene are strongly associated with children presenting to
hospitals with infection, and these mutations increase susceptibility to infection in
children who are heterozygous or homozygous for the mutations.101 This increased
risk of infection may be of greatest importance when immune responses are either
immature (such as in the neonate) or defective. Recent reports have described
associations between low-producing MBL alleles and disease severity in conditions
in which immunity is already significantly impaired.102,103 Low-producing alleles
of MBL may also influence the clinical phenotype of other immunodeficiency
diseases.94
Only one study has investigated the role of MBL haplotypes in the development
of cerebral palsy.104 Our large case-control study found that MBL haplotype LYPA
was associated with all types of cerebral palsy (OR 1.57, 95% CI 1.00–2.46), and also
with preterm hemiplegic cerebral palsy (OR 2.77, 95% CI 1.02–7.26) (Table 3).104 The
defective HYPD haplotype was associated with quadriplegic cerebral palsy (OR 3.47,
95% CI 1.41–8.31). Furthermore, when subanalysis on samples previously testing
positive for exposure to viral infection was conducted, similar patterns of significance
were observed, whereas analysis on samples negative for exposure to viral infection
showed no positive associations.104 This suggests that both genetic susceptibility
factors and exposure to viral infection are necessary to significantly increase the
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risk of cerebral palsy. It also suggests that the associations between MBL haplotypes
and cerebral palsy are mediated through modifications of the immune response to
infection. Further research is required to investigate these hypotheses.
VIRAL INFECTION AND THE FETAL RESPONSE TO INFECTION
FIRS is described as a multisystem disorder that may result in preterm delivery and/or
neurological complications, such as cerebral palsy.105 Histopathological evidence of
this inflammatory response is present when funisitis (inflammation of the umbilical
cord) and chorioamnionitis are confirmed. It is characterised by increased levels
of proinflammatory blood cells in the amniotic fluid and the accumulation of
inflammatory blood cells (polymorphonuclear leukocytes) in the umbilical cord and
chorion.106 These have been associated with increased risks of both neonatal infection
and the development of cerebral palsy.107,108 The fetal inflammatory response to
intra-amniotic infection is biologically important, even more so than the maternal
inflammatory response.109 Amulticentre cohort of 1078 infants of birthweight<1500
g showed that, in preterm births, abnormal fetal inflammatory responses contribute
to cerebral white matter damage and that fetal responses to maternal infection can
damage the fetal brain without the presence of fetal brain infection.109 Evidence is
also accumulating for the fetal role in chorioamnionitis. In the past, chorioamnionitis
has been assumed to represent a maternal infection,110 but it is now apparent that
it is primarily a fetal inflammatory response.28 The onset of spontaneous preterm
labour with preterm premature rupture of membranes is preceded by a systemic
proinflammatory cytokine response in the fetus, which is probably the fetal response
to the presence of microbial products.111 Antenatal infection and brain white matter
damage appear to be linked by the FIRS.62 Umbilical vein plasma concentrations
of interleukin-6, a cytokine implicated in the regulation of the host response to
infection, are increased in neonates born tomotherswith clinical chorioamnionitis,112
also suggesting that the inflammatory process causing chorioamnionitis is a fetal
response.
In addition to the FIRS, intrauterine infection is postulated to be an important
contributor to the development of cerebral palsy, and is currently the focus of
intensive research. To date, many studies have investigated the role of infection
in the development of cerebral palsy by using surrogate markers of infection, such
as chorioamnionitis and maternal pyrexia. Chorioamnionitis can be described as
histopathological evidence of infection, characterised by an inflammatory leukocyte
infiltration of the chorion and amnion. Chorioamnionitis can make an infant of very
low birth weight more vulnerable to neurologic damage113 and increase the risk of
cerebral palsy.114–116 Also, a combination of maternal chorioamnionitis and neonatal
seizures identifies infants of very low birth weight who are at increased risk of cerebral
palsy.115,117 Further evidence for the role of intrauterine infection in brain damage and
cerebral palsy comes from an experiment which induced intrauterine infection in
rabbits by injecting doses of Escherichia coli bacteria. This experiment showed that
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bacterial infection can lead to fetal white matter damage in the brain,118 providing
more evidence for the role of intrauterine infection as a cause of cerebral palsy. Ameta-
analysis investigated the potential association between chorioamnionitis and cerebral
palsy in both full term and preterm infants.119 This meta-analysis has since been
revisited and now includes studies published in 2000.120 Clinical chorioamnionitis
was found to be significantly associated with cerebral palsy (relative risk 1.9, 95%
CI, 1.5–2.5), and also cystic periventricular leukomalacia (relative risk 2.6, 95%
CI, 1.7–3.9), demonstrating that chorioamnionitis is a risk factor for both cerebral
palsy and cystic periventricular leukomalacia.120 A more recent case-control study in
extremely low birthweight infants has also demonstrated strong associations between
cerebral palsy and chorioamnionitis, both clinical and histological (OR 3.71, 95%
CI 1.16–11.9). Intrauterine exposure to maternal infection has also been associated
with an increased risk of long-term neurologic morbidity.14 A study by Yanowitz
and colleagues121 in 2002 found that chorioamnionitis was associated with increased
cytokine concentrations in cord blood and that infants with fetal vessel inflammation
had higher levels of proinflammatory cytokines. The risk of brain injury in premature
infants born after chorioamnionitis is apparently increased when cerebrovascular
inflammation and systemic vasculitis are both present.121 Maternal infection is
associated with white matter damage, periventricular leukomalacia, and long-term
neurological dysfunction and cerebral palsy. It is still not clear if the brain damage
is secondary to the proinflammatory cytokine response to the initial infection.17,122
Infection remote from the brain results in the release of products of infection into
the circulation. These products may cross the blood-brain barrier, either as a result of
immaturity of this barrier,123 or due to release of proinflammatory cytokines, which
impair its integrity.69,77 Having penetrated the blood-brain barrier, these products
of infection, which include proinflammatory cytokines such as TNF-, can cause
damage to developing white matter, in the form of periventricular leukomalacia. This
white matter damage may result from a number of different mechanisms, including
direct tissue damage, stimulation of fetal microglia to produce more TNF-,105 and
disruption of the endothelium and/or ependyma.77
During pregnancy, maternal resistance to some viral infections is decreased,
subsequent to depression of cell-mediated immunity with consequent reactivation of
latent virus or increased susceptibility to primary infection (if non-immune). As such,
the fetusmay be at risk of transplacental virus transmission.124 There aremany viruses
capable of causing damage to the brain, in particular the developing brain, and these
are referred to collectively as neurotrophic viruses.125 Many neurotrophic viruses are
capable of causing brain damage in the human fetus. The list includes rubella virus,
cytomegalovirus, varicella zoster virus, enteroviruses, adenoviruses, rotaviruses, and
othermembers of the herpesvirus group.126 More recently the arenavirus (lymphocytic
choriomeningitis virus) has been added to the list.127
For a pathogen to cause fetal damage in utero, it must cross the placenta or fetal
membranes. This may occur during the viraemic, bacteraemic, or parasitic phase
of maternal infection.128 The placenta acts as a potential barrier to maternal/fetal
infection. However this barrier may be less effective in early pregnancy during its
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Table 4 Significant odds ratios and 95% confidence intervals for associations between exposure
to perinatal viral exposure and cerebral palsy
Virus
Gestational Age
(weeks) Type of Cerebral Palsy Odds Ratio (95% CI)
Herpes PCR Group B All All Cerebral Palsy 1.68 (1.09–2.59)
Diplegia 1.93 (1.03–3.61)
Hemiplegia 2.07 (1.10–3.88)
≥37 Diplegia 2.45 (1.02–5.89)
Hemiplegia 2.38 (1.15–4.92)
<37 Quadriplegia 2.87 (1.09–7.59)
Any herpesvirus ≥37 All Cerebral Palsy 1.52 (1.09–2.13)
Any virus All All Cerebral Palsy 1.64 (1.17–2.28)
≥37 All Cerebral Palsy 1.30 (1.00–1.67)
Herpes PCR Group B = varicella-zoster virus, human herpesvirus −6 or −7; Any herpesvirus =
herpes simplex viruses 1 and 2, Epstein-Barr virus, cytomegalovirus, varicella-zoster virus, human
herpesvirus −6, −7 or −8; Any virus = any herpesvirus or enterovirus.
development, and potentially when the placenta is damaged by vascular disease, e.g.,
infarction. Placental dysfunction has been associated with thrombophilia, systemic
lupus erythematosus (SLE), diabetes, chronic hypoxia, and severe preeclampsia.
Disruption of the placental barrier may increase the vulnerability of the fetus to
maternal infection. In addition, gestational age at the time of maternal infection plays
an important role in the development of fetal infection. Although fetal transmission
is much higher in infections contracted in the third trimester, exposure to fetal
infection in the first or early second trimester is more likely to cause severe fetal
damage and miscarriage.128 This gestational age effect may explain in part why not
all patients with potentially damaging infections go on to develop severe neurological
sequelae such as periventricular leukomalacia and cerebral palsy because the brain
may bemore vulnerable during specific periods of fetal or neonatal brain development.
Cytomegalovirus, herpes simplex viruses, varicella zoster virus, adenovirus, and
enterovirus are all capable of crossing the placenta and infecting the fetus.129–136 The
likelihood of maternal infection resulting in infection of the fetus varies according to
the specific virus, whether the infection is primary or recurrent, and the gestational
age of the fetus at the time of infection. Once the infection has crossed the placenta
into the fetal circulation, there is the potential for damage, both by the infectious
agent directly, and also by the FIRS. Some viruses can persist for months or years after
the initial infection.137–144 These viruses may have effects as long as 30 years after the
original infection.138,139,142–144
Our large retrospective case control study of cerebral palsy cases and controls
identified associations between perinatal exposure to neurotropic viruses and cerebral
palsy.145 In particular, the detection of Herpes PCR Group B viruses (Varicella zoster
virus, human herpesvirus 6 or human herpesvirus 7) increased the risk of developing
cerebral palsy, with an OR of 1.68 (95% CI 1.09–2.59) (Table 4). These findings suggest
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the possibility of complex relationships between exposure to viral infections and
cerebral palsy development, and are worthy of further investigation.
FUTURE RESEARCH
Most of the associations between cerebral palsy and thrombophilia, cytokine
polymorphisms and perinatal viral exposure in our studies have been derived from
analyses of a large retrospective case-control cohort and has involved multiple
comparisons. In some subanalyses, numbers of cases have been small. Therefore,
type I and II errors are possible. This necessitates larger prospective studies where
there is specific a priori testing of the hypothesised associations. Such a large study
is underway in Australia and will help confirm or refute these risk factors as possible
causative factors in cerebral palsy. The collection of more clinical data and known
clinical risk factors such as multiple pregnancy, infections, fetal growth restriction
etc will allow better assessment of the interaction of known environmental cerebral
palsy risk factors and these possible new genetic risk factors.
PREVENTION
The current understanding of these possible genetic susceptibility factors for cerebral
palsy and their interaction with environmental risk factor such as viral exposure in
pregnancy supports the “double or triple jeopardy” hypothesis where a combination
of risk factors at different gestations can lead to the different types of neuropathology
that in turn lead to the different types of cerebral palsies. Confirmation of this
hypothesis may lead to preventative strategies. Large scale immunisation is effective
in reducing adverse effects of infection with viral agents, as evidenced by the
rubella virus vaccine reducing the teratogenic effects of rubella during pregnancy.
Children are already being immunised against varicella-zoster virus, and it will be
of interest to observe if there is a decline in adverse pregnancy outcome rates,
including cerebral palsy, in the next generation following the vaccination of their
mothers. The introduction of vaccines for a wide range of viruses and bacteria would
reduce the risk of women contracting infection during pregnancy, and therefore min-
imise the risk of transplacental transfer of infection to the fetus. Antiviral therapies,
if their safety can be established, may also play a role in reducing the risk of adverse
outcomes.
The reported associations between inherited thrombophilic and cytokine
polymorphisms and adverse outcomes need to be confirmed in further large-scale
studies. There remain many more candidate polymorphisms worthy of investigation,
in order to fully understand any potential interactions between these genetic factors
and the subsequent development of adverse pregnancy outcomes. If any of these
polymorphisms are shown to be clinically relevant, intervention strategies can be
implemented to reduce the risk of these polymorphisms contributing to adverse
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events. Although still controversial, antithrombotic therapy may be useful to women
identified as having an increased risk of thrombosis. Fetal genetic screening in
utero of these high-risk women may also be useful. It should be emphasized
that current antithrombotic therapy using low-molecular weight heparins will
potentially only “protect” the uteroplacental circulation and will not protect the
fetus from (theoretical) adverse effects of fetoplacental thrombosis. Perhaps novel
antithrombotic strategies such as ultra-low molecular weight heparins and other
direct antithrombins may be able to prevent fetoplacental thrombosis without the
extremely adverse consequences seen with the use of warfarin. Fetal genetic screening
in utero for cytokine polymorphisms such as TNF--308 and polymorphisms
in the MBL gene may also provide clinicians with more clinically relevant
treatment options. Prophylactic antiviral or antibiotic treatment may be considered
during pregnancy for women with cytokine polymorphisms capable of altering
the immune response to infection. Lastly, if our ongoing studies show maternal
polymorphisms are involved, then prenatal gene therapy may be a future goal for
prevention.
CONCLUSIONS
Research into the antenatal causes of cerebral palsy has shown that inherited
thrombophilias, inherited cytokine polymorphisms and viral infections are all
associated with the subsequent development of cerebral palsy. Future research should
investigate interactions between genes and the environment, whichmay create double
or multiple jeopardy for cerebral palsy. Possible preventative strategies should be
explored, including vaccination programmes against neurotropic viruses identified
as being associated with cerebral palsy. This research also has medico-legal and
political implications. The possible causal pathways for most cerebral palsy outcomes
currently cannot be influenced by obstetric practice. Determination of the antenatal
causes of cerebral palsy, with the possible advent of prenatal screening, may lead to its
eventual prevention, saving much human suffering and saving hundreds of millions
of dollars annually.
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